Perlara embarks on journeys of discovery called PerlQuests™ with families, patient organizations and researchers to develop treatments for rare diseases.
There are about 7000 rare diseases affecting 350 million people worldwide, of which roughly half are inherited, i.e. relating to genes. Until now, the cost of discovering chemical compounds that might be safe and effective candidates for the development of an FDA approved drug therapy has been too high for “rare” diseases affecting small populations. At the current rate of new drug approvals, it will take another 450 years before drugs are approved for all rare diseases.
Our PerlArk™ Drug Discovery Platform increases the speed and lowers the cost of cure discovery by rapidly screening thousands of potential drug candidates, providing new hope for millions of rare disease patients.
We have identified at least 250 single-gene diseases that fit our PerlArk™ Platform. These diseases share some overlap with common diseases, allowing us to begin the quest for treatments for over 1000 diseases. Our first PerlQuests target Niemann-Pick C Disease (NPC) and Niemann-Pick A Disease (NPA), lysosomal storage disorders, NGLY1 Deficiency, a metabolic disease related to proteasome-mediated degradation, and PMM2-CDG, a congenital disorder of glycosylation. What we are learning from the NPC PerlQuest may lead to drug candidates for Alzheimer’s disease.
Let’s PerlQuest together
Still have questions about PerlQuests?
Perlara Enters Collaboration with the University of Notre Dame Focused on Cori Disease and Pompe Disease
Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency
Research updates from our Blog
The 2018 Yeast Genetics Meeting (#Yeast18) was held in August at Stanford University in Palo Alto. I learned about the latest developments in research and advances in tools and technology, reconnected with former colleagues, and established new connections and...
The Global Genes 2018 RARE Patient Advocacy Summit – one of the key events in the rare disease world – wraps up today. As the largest worldwide gathering of rare disease patients, advocates, and thought leaders, the summit brought together over 100 experts, who led...
Last week, we posted a preprint describing new yeast models of Phosphomannomutase 2 Deficiency, or PMM2-CDG, the most common congenital disorder of glycosylation in the world. This PMM2 model preprint is our second preprint on bioRxiv which, for the uninitiated,...